These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16181243)

  • 1. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients.
    Gatta B; Hau DH; Catargi B; Roger P; Tabarin A
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):477-8. PubMed ID: 16181243
    [No Abstract]   [Full Text] [Related]  

  • 2. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P; Alves Martins MR; Abucham J
    Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
    Minniti G; Jaffrain-Rea ML; Baldelli R; Ferretti E; Caracciolo B; Bultrini A; Gulino A; Tamburrano G
    Clin Ter; 1997 Dec; 148(12):601-7. PubMed ID: 9528195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline treatment in acromegaly: pros.
    Marazuela M; Ramos-Leví A; Sampedro-Núñez M; Bernabeu I
    Endocrine; 2014 Jun; 46(2):215-9. PubMed ID: 24532103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline treatment in acromegaly: cons.
    Kasuki L; Vieira Neto L; Gadelha MR
    Endocrine; 2014 Jun; 46(2):220-5. PubMed ID: 24504766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS; Bronstein MD
    Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth-hormone and prolactin excess.
    Colao A; Lombardi G
    Lancet; 1998 Oct; 352(9138):1455-61. PubMed ID: 9808008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
    Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
    Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
    Esposito V; Esposito D; Lo Iudice G
    Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for dopamine agonists in the treatment of acromegaly.
    Jaquet P
    J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
    Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
    Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients.
    Halperin I; Nicolau J; Casamitjana R; Sesmilo G; Serra-Prat M; Palomera E; Puig-Domingo M
    Horm Metab Res; 2008 Jun; 40(6):422-6. PubMed ID: 18393173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of combination medical therapy in acromegaly: hope for the nonresponsive patient.
    Fleseriu M
    Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):321-9. PubMed ID: 23807604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.